Abstract
Ninety per cent of US prescriptions volumes are generic drug products. Solid oral products constitute more than 75% of the generic drugs. The generic product development and commercialization incorporate complex process steps that need close portfolio management, alignment and monitoring. With increased regulatory actions, market insecurity and pricing pressures, generic organizations are required to apply evidence based new empirical approaches to product development and portfolio management. Watergile approach discussed in this article allows generic organizations to adapt, respond and evolve based on emerging conditions while delivering much needed affordable drug products to the end patient.
Get full access to this article
View all access options for this article.
